Vertex Pharmaceuticals Incorporated

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1989-01-01

Employees: 5.4K

Market Cap: $123.9B

Website: http://www.vrtx.com

Clinical Trials

Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)

Phase 3

Conditions: Diabetic Peripheral Neuropathic Pain

Interventions: Drug: Suzetrigine

First Posted Date: 2024-11-20

Last Posted Date: 2024-12-18

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 300

Registration Number: NCT06696443

Locations: 🇺🇸
Healthcare Research Network II, LLC, Flossmoor, Illinois, United States
🇺🇸
MedVadis Research Corporation, Waltham, Massachusetts, United States
🇺🇸
The Center for Clinical Research, Winston-Salem, North Carolina, United States

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

Phase 3

Recruiting

Conditions: Diabetic Peripheral Neuropathic Pain

Interventions: Drug: Suzetrigine
Drug: Pregabalin
Drug: Placebo (matched to Pregabalin)
Drug: Placebo (matched to SUZ)

First Posted Date: 2024-10-08

Last Posted Date: 2024-12-20

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 1100

Registration Number: NCT06628908

Locations: 🇺🇸
Pinnacle Research Group, LLC, Anniston, Alabama, United States
🇺🇸
Synexus Clinical Research US - Birmingham, Birmingham, Alabama, United States
🇺🇸
Synexus Clinical Research US - Phoenix Central, Phoenix, Arizona, United States

and more 55 locations

Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

Phase 2

Recruiting

Conditions: Diabetic Peripheral Neuropathic Pain

Interventions: Drug: VX-993
Drug: Pregabalin
Drug: Placebo (matched to pregabalin)
Drug: Placebo (matched to VX-993)

First Posted Date: 2024-10-01

Last Posted Date: 2024-12-10

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 300

Registration Number: NCT06619860

Locations: 🇺🇸
AMR Fort Myers (The Clinical Study Center), Fort Myers, Florida, United States
🇺🇸
Innovation Medical Research Center, Palmetto Bay, Florida, United States
🇺🇸
ARSN - NeuroStudies, Decatur, Georgia, United States

and more 8 locations

A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy

Phase 2

Recruiting

Conditions: Acute Pain

Interventions: Drug: VX-993
Drug: HB/APAP
Drug: Placebo (matched to HB/APAP)
Drug: Placebo (matched to VX-993)

First Posted Date: 2024-10-01

Last Posted Date: 2024-11-28

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 355

Registration Number: NCT06619847

Locations: 🇺🇸
Woodland International Research Group, Little Rock, Arkansas, United States
🇺🇸
BioBehavioral Research of Austin, Austin, Texas, United States
🇺🇸
HD Research LLC | Legent Orthopedic Hospital, Carrollton, Texas, United States

and more 7 locations

A Phase 1 Dose Escalation Study of VX-973 in Healthy Participants

Phase 1

Recruiting

Conditions: Pain

Interventions: Drug: VX-973
Drug: Placebo

First Posted Date: 2024-09-26

Last Posted Date: 2024-10-29

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 40

Registration Number: NCT06615570

Locations: 🇺🇸
ICON Salt Lake City, Salt Lake City, Utah, United States

Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment

Phase 1

Recruiting

Conditions: Hepatic Impairment

Interventions: Drug: IXP

First Posted Date: 2024-07-31

Last Posted Date: 2024-10-24

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 40

Registration Number: NCT06529796

Locations: 🇺🇸
Division of Clinical Pharmacology, University of Miami, Miami, Florida, United States
🇺🇸
GCP Research, Saint Petersburg, Florida, United States
🇺🇸
Texas Liver Institute, San Antonio, Texas, United States

Evaluation of the Pharmacokinetic Drug-drug Interactions Between VX-993 and Metformin in Healthy Adults

Phase 1

Recruiting

Conditions: Pain

Interventions: Drug: VX-993
Drug: Metformin

First Posted Date: 2024-07-26

Last Posted Date: 2024-10-30

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 32

Registration Number: NCT06523595

Locations: 🇺🇸
ICON Salt Lake City, Salt Lake City, Utah, United States

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993

Phase 1

Completed

Conditions: Pain

Interventions: Drug: VX-993

First Posted Date: 2024-07-18

Last Posted Date: 2024-10-10

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 24

Registration Number: NCT06508762

Locations: 🇺🇸
ICON Salt Lake City, Salt Lake City, Utah, United States

Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)

Recruiting

Conditions: Cystic Fibrosis

First Posted Date: 2024-07-17

Last Posted Date: 2024-12-18

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 150

Registration Number: NCT06506773

Locations: 🇳🇿
Starship Children's Hospital, Grafton, New Zealand
🇩🇪
Klinikum Westbrandenburg (CF), Potsdam, Germany
🇺🇸
Johns Hopkins All Children's Hospital Outpatient Care Center, Saint Petersburg, Florida, United States

and more 44 locations

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older

Phase 3

Conditions: Cystic Fibrosis

Interventions: Drug: ELX/TEZ/IVA
Drug: IVA

First Posted Date: 2024-06-14

Last Posted Date: 2024-12-20

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 50

Registration Number: NCT06460506

Locations: 🇦🇺
The Kids Research Institute Australia, Nedlands, Australia
🇨🇭
Kinderspital Zurich, Zurich, Switzerland
🇬🇧
Children and Young Adults Research Unit, Cardiff, United Kingdom

and more 2 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy